Asset Details
Do you wish to reserve the book?
Apalutamide radio-sensitisation of prostate cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Apalutamide radio-sensitisation of prostate cancer
Do you wish to request the book?
Apalutamide radio-sensitisation of prostate cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Apalutamide radio-sensitisation of prostate cancer
2021
Overview
Introduction
The combination of radiotherapy with bicalutamide is the standard treatment of prostate cancer patients with high-risk or locally advanced disease. Whether new-generation anti-androgens, like apalutamide, can improve the radio-curability of these patients is an emerging challenge.
Materials and methods
We comparatively examined the radio-sensitising activity of apalutamide and bicalutamide in hormone-sensitive (22Rv1) and hormone-resistant (PC3, DU145) prostate cancer cell lines. Experiments with xenografts were performed for the 22Rv1 cell line.
Results
Radiation dose–response viability and clonogenic assays showed that apalutamide had a stronger radio-sensitising activity for all three cell lines. Confocal imaging for γΗ2Αx showed similar DNA double-strand break repair kinetics for apalutamide and bicalutamide. No difference was noted in the apoptotic pathway. A striking cell death pattern involving nuclear karyorrhexis and cell pyknosis in the G1/S phase was exclusively noted when radiation was combined with apalutamide. In vivo experiments in SCID and R2G2 mice showed significantly higher efficacy of radiotherapy (2 and 4 Gy) when combined with apalutamide, resulting in extensive xenograft necrosis.
Conclusions
In vitro and in vivo experiments support the superiority of apalutamide over bicalutamide in combination with radiotherapy in prostate cancer. Clinical studies are encouraged to show whether replacement of bicalutamide with apalutamide may improve the curability rates.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Anilides - administration & dosage
/ Animals
/ Biomedical and Life Sciences
/ Cell Proliferation - drug effects
/ Cell Survival - drug effects
/ Dose-Response Relationship, Radiation
/ Humans
/ Male
/ Mice
/ Nitriles - administration & dosage
/ Oncology
/ Patients
/ Prostatic Neoplasms - therapy
/ Radiation-Sensitizing Agents - administration & dosage
/ Radiation-Sensitizing Agents - pharmacology
/ S phase
/ Thiohydantoins - administration & dosage
/ Thiohydantoins - pharmacology
/ Tosyl Compounds - administration & dosage
/ Tosyl Compounds - pharmacology
